ABVC BioPharma Inc. (ABVC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, ABVC scores 32 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows. Fundamental cash engine: 7 out of 20, reflecting ROIC of -35% and an FCF yield of -10.76%. Whale / 13F flow: 6 out of 20, described as institutional accumulation and options positioning. Insider conviction: 3 out of 20, based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit: 6 out of 20, reflecting Beta of 1.0 and sector sensitivity. Forensic balance sheet: 10 out of 20, citing Altman Z of 2.5, Piotroski F of 1/9, and Debt/Equity of 0.5.

For a prospective investor evaluating the stock today, the rating points to a company whose cash generation is negative, whose profitability metrics are weak, and whose insider signal is the weakest of the five pillars. The highest-scoring pillar (forensic balance sheet) still sits at half its maximum, and the Piotroski reading of 1 out of 9 is a notable red flag on operating quality. Upside drivers implied by the data are limited to the balance-sheet pillar and the modest whale-flow reading; valuation tradeoffs are shaped by a market capitalization of $27.8M against negative free cash flow and an operating loss in each reported period. Any ripple from sector sensitivity is captured only at the macro-fit pillar and is not quantified further in the source data.

Per the recent news and catalysts section, the news wire contains five items, all tagged to ABVC. The most material items concern financing activity. One item, tagged as a risk watch item, reports the closing of a private placement of original issue discount senior convertible promissory notes for gross proceeds of $3.39 million. A separate headline reports a $4.11 million convertible note financing. A third item, tagged as a catalyst, repeats the $3.39 million raise. Two further items are market wire notices, including an 8-K filing dated 2 November. The primary market wire item is a stock options chain page with no substantive content in the summary. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no supply-chain links recorded.

• What is the source of the $0.0M revenue in FY 2025, and what product or service does ABVC sell?
• What are the terms and dilution implications of the convertible note financings reported in the news wire?
• What are the current debt obligations, given that debt is listed as N/A in every reported period?
• What explains the FY 2025 cash balance of $0.7M relative to negative free cash flow of $-3.0M, and how is the company funding operations?
• Are there any analyst estimates, ownership disclosures, or insider transactions available to corroborate the RQD pillar readings?